Case Type: Mergers & Acquisitions

Akers Biosciences, Inc. (AKER) relating to its proposed acquisition by MyMD Pharmaceuticals. Under the terms of the agreement, Akers shareholders are expected to own only 20% of the combined company.

Tengasco, Inc. (TGC) relating to its proposed merger with Riley Exploration – Permian, LLC. Under the terms of the agreement, Tengasco shareholders will only own 5% of the combined company.

Urovant Sciences Ltd. (UROV) relating to its proposed acquisition by Sumitovant Biopharma Ltd. Under the terms of the agreement, Urovant shareholders are expected to receive approximately $16.25 in cash per share.

Emisphere Technologies, Inc. (EMIS) relating to its proposed merger with Novo Nordisk A/S. Under the terms of the agreement, Emisphere shareholders are expected to receive approximately $7.82 in cash per share.

Switchback Energy Acquisition Corporation (SBE) relating to its proposed merger with ChargePoint, Inc. Under the terms of the agreement, Switchback Energy shareholders will own approximately 10.3% of the combined company.

AMCI Acquisition Corporation (AMCI) relating to its proposed merger with Advent Technologies, Inc. Under the terms of the agreement, AMCI shareholders will own approximately 31% of the combined company.

LifeSci Acquisition Corporation (LSAC) relating to its proposed merger with Vincera Pharma, Inc. Under the terms of the agreement, Vincera shareholders will own approximately 40% of the combined company.

Navistar International Corporation (NAV) relating to its proposed acquisition by TRATON SE, Inc. Under the terms of the agreement, Navistar shareholders will receive $44.50 per share in cash.

CIT Group, Inc. (CIT) relating to its proposed acquisition by First Citizens BancShares, Inc. Under the terms of the agreement, CIT shareholders will receive 0.0620 shares of FCNCA per share of CIT common stock.

Haymaker Acquisition Corp. II (HYAC) relating to its proposed acquisition of Arko Holdings, Ltd. Under the terms of the agreement, Haymaker will acquire Arko through a reverse merger that will result in Arko becoming a publicly-traded company with a pro forma enterprise value of approximately $2 billion.